IRF4 and neoplasm: For example, IRF4 exhibited promoter hypomethylation in KIRP and THCA, no significant changes in promoter methylation in GBM, PCPG, SARC and SKCM, and high methylation levels in several tumours including BLCA, BRCA, CESC and COAD.